国邦医药(605507) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 reached ¥1,440,055,937.13, representing a year-on-year increase of 7.57% compared to ¥1,338,703,044.52 in the same period last year[4] - Net profit attributable to shareholders was ¥214,977,071.32, an increase of 8.17% from ¥198,731,128.32 in the previous year[4] - The basic earnings per share for the period was ¥0.38, reflecting a growth of 5.56% from ¥0.36 in the same period last year[4] - Net profit for Q1 2025 was ¥214,259,675.01, compared to ¥198,578,686.05 in Q1 2024, representing an increase of 7.9%[15] - The total comprehensive income for Q1 2025 was ¥214,259,675.01, compared to ¥198,578,686.05 in Q1 2024, indicating an increase of about 7.9%[17] - Basic and diluted earnings per share for Q1 2025 were both ¥0.38, up from ¥0.36 in Q1 2024, reflecting a growth of approximately 5.6%[17] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥11,114,683,956.54, a 3.10% increase from ¥10,780,436,167.58 at the end of the previous year[5] - The total assets as of March 31, 2025, amounted to ¥11,114,683,956.54, an increase from ¥10,780,436,167.58 as of December 31, 2024[12] - Current assets totaled ¥6,261,211,433.94 as of March 31, 2025, compared to ¥5,874,299,808.13 at the end of 2024, indicating a growth of 6.6%[12] - Total liabilities as of March 31, 2025, were ¥2,855,407,805.99, up from ¥2,728,378,918.95 at the end of 2024, marking an increase of 4.7%[13] - The total non-current assets as of March 31, 2025, were ¥4,853,472,522.60, a slight decrease from ¥4,906,136,359.45 at the end of 2024[12] Shareholder Information - The equity attributable to shareholders increased to ¥8,255,276,580.42, up 2.58% from ¥8,047,340,282.19 at the end of the previous year[5] - The company had a weighted average return on equity of 2.64% for the reporting period, unchanged from the previous year[5] - The total number of common shareholders at the end of the reporting period was 26,003[8] - The top ten shareholders held a combined 68.27% of the company's shares, with New Chang Ande Trading Co., Ltd. being the largest shareholder at 23.08%[8] Cash Flow - The cash flow from operating activities showed a negative net amount of ¥351,671,764.52, compared to a negative ¥79,114,596.07 in the same period last year[4] - Cash inflows from operating activities for Q1 2025 totaled ¥1,083,518,233.35, compared to ¥1,058,961,855.16 in Q1 2024, showing an increase of about 2.3%[20] - The net cash outflow from operating activities for Q1 2025 was ¥351,671,764.52, worsening from a net outflow of ¥79,114,596.07 in Q1 2024[20] - Cash inflows from investment activities in Q1 2025 were ¥5,232,113,917.55, significantly higher than ¥193,197,809.94 in Q1 2024, marking an increase of approximately 2,617.5%[20] - The net cash outflow from investment activities for Q1 2025 was ¥161,974,354.35, compared to a net inflow of ¥4,383,206.15 in Q1 2024[21] - Cash inflows from financing activities for Q1 2025 amounted to ¥560,269,185.23, compared to ¥203,530,000.00 in Q1 2024, indicating an increase of about 174.5%[21] - The net cash flow from financing activities for Q1 2025 was ¥266,504,839.90, up from ¥74,112,521.75 in Q1 2024, reflecting an increase of approximately 260.5%[21] - The ending cash and cash equivalents balance for Q1 2025 was ¥1,292,335,945.26, down from ¥1,706,747,877.14 in Q1 2024, representing a decrease of about 24.3%[21] Research and Development - Research and development expenses for Q1 2025 were ¥38,737,666.55, slightly up from ¥37,654,589.30 in Q1 2024, indicating a focus on innovation[16] - The company reported a financial income of ¥6,953,524.35 in Q1 2025, down from ¥10,769,739.38 in Q1 2024, showing a decrease of 35.5%[16] Non-Recurring Items - Non-recurring gains and losses totaled ¥11,234,930.21 for the period, with significant contributions from government subsidies and fair value changes of financial assets[6]